Form 4: ATAI Life Sciences CFO Modifies Stock Option Expiration Dates

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., reports adjustments to the expiration dates of her pre-IPO stock options to align with the company's 2021 Incentive Award Plan.

Summary

• Anne Nagengast Johnson, the Chief Financial Officer of ATAI Life Sciences N.V., has reported changes in her beneficial ownership of derivative securities.
• The reported transactions involve the extension of the expiration dates of certain pre-IPO stock options.
• These adjustments align the pre-IPO options with the company's 2021 Incentive Award Plan, reflecting prevailing market practices.
• Specifically, the expiration dates of options for 326,416 shares at an exercise price of $5.68 and 115,152 shares at an exercise price of $11.71 were extended from August 20, 2025, to August 20, 2030.
• No new stock options were awarded in these transactions.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The extension of stock option expiration dates is a common practice and suggests a focus on employee retention and alignment with company incentives. There are no explicitly negative aspects mentioned.

Positives

• The extension of stock option expiration dates aligns with the company's 2021 Incentive Award Plan.
• The alignment of stock option terms with market practices could be seen as a positive move for employee retention and motivation.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Management Comments

• The transactions reported herein reflect the extension of the expiration date of certain pre-IPO stock options to align them with options granted under the Issuer's 2021 Incentive Award Plan, which is consistent with prevailing market practices.

Industry Context

Extending the expiration dates of stock options to align with standard incentive plans is a common practice to retain key employees, particularly in the biotech industry where long-term growth and development are crucial.

Comparison to Industry Standards

• Many biotech companies use incentive plans with similar vesting schedules and option terms to attract and retain talent.
• Companies like Moderna and BioNTech also have stock option plans with similar features, including vesting schedules and expiration dates tied to long-term performance.
• The extension of option expiration dates is a fairly standard practice to ensure alignment with company goals and employee incentives.

Stakeholder Impact

• Shareholders may view the alignment of stock options with the incentive plan as a positive step towards retaining key personnel.
• Employees holding these options benefit from the extended expiration dates, providing more time to realize potential gains.
• The company benefits from aligning incentives with long-term performance.

Key Dates